FDA Grants Priority Review to Zilganersen for Alexander Disease, Setting Stage for First Treatment
Key Insights
The FDA has accepted Ionis Pharmaceuticals (search)' New Drug Application for zilganersen with Priority Review designation, setting a PDUFA date of September 22, 2026 for the first potential treatment of Alexander disease (search).
In pivotal trials, zilganersen 50 mg demonstrated statistically significant stabilization of gait speed compared to control, with a 33.3% improvement (p=0.0412) at week 61 in patients with this rare, progressive neurological condition.
Alexander disease (search) affects approximately 1 per 1-3 million people worldwide and currently has no approved disease-modifying treatments, with patients typically dying within 14-25 years after symptom onset.
Ionis Pharmaceuticals (search) announced that the U.S. Food and Drug Administration has accepted for Priority Review the New Drug Application for zilganersen, an investigational RNA-targeted medicine for Alexander disease (search) (AxD). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of September 22, 2026, potentially bringing the first treatment option to patients with this rare, progressive and often fatal neurological condition.
Pivotal Trial Results Drive Regulatory Milestone
The NDA and Priority Review designation were based on results from a global, multicenter, randomized, double-blind, controlled Phase 1-3 study that enrolled 54 participants with Alexander disease (search) between the ages of 1.5 and 53 years across 13 sites in eight countries. Most participants in the study were children, reflecting the early onset and severe progression of AxD in pediatric populations.
In the pivotal study, zilganersen 50 mg demonstrated statistically significant and clinically meaningful stabilization on the primary endpoint of gait speed as assessed by the 10-Meter Walk Test (10MWT) compared to control at week 61, with a least square mean difference of 33.3% (p=0.0412). The treatment also showed favorable safety and tolerability profiles.
Results across key secondary and exploratory endpoints evaluating adaptive function, communication, gastrointestinal symptoms, sleep and seizures consistently favored zilganersen. The study design included participants randomized in a 2:1 ratio to receive zilganersen or control for a 60-week double-blind treatment period, with two dose cohorts of 25 mg and 50 mg administered every 12 weeks.
Addressing Critical Unmet Medical Need
"Alexander disease (search) is a devastating condition, commonly resulting in progressive motor and cognitive dysfunction, loss of independence and is often fatal. There are no approved disease-modifying treatments, underscoring the significant unmet need in this community," said Brett Monia, Ph.D., chief executive officer of Ionis.
Alexander disease (search) is a rare neurological condition that occurs in approximately 1 per 1 to 3 million people worldwide and affects astrocytes, a type of brain cell that supports neurons and oligodendrocytes. The disease is caused by disease-causing variants in the glial fibrillary acidic protein (search) (GFAP (search)) gene and is characterized by progressive neurological deterioration resulting in loss of functional mobility, loss of independence and the inability to control muscles for large movements, swallowing and airway protection. AxD usually leads to death within 14-25 years after symptom onset.
Mechanism of Action and Regulatory Recognition
Zilganersen is an investigational antisense oligonucleotide medicine designed to inhibit production of excess glial fibrillary acidic protein (search) (GFAP (search)) that accumulates because of disease-causing variants in the GFAP gene. The FDA has previously granted zilganersen Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations, while the European Medicines Agency granted Orphan Drug designation.
Priority Review designation is granted to marketing applications for medicines that, if approved, would provide a significant improvement in the safety or effectiveness of treatment, prevention or diagnosis of a serious condition. This designation enables the FDA to take action within six months, compared to 10 months under standard review.
Commercial and Strategic Implications
"If approved, zilganersen will be the first and only treatment for Alexander disease (search), marking a breakthrough for patients. It would also mark Ionis' first independent commercial launch in neurology, an important milestone that strengthens our neurology franchise and supports our goal to deliver a steady cadence of transformational medicines to people with serious diseases," Monia added.
The potential approval would expand Ionis' neurology portfolio, which already includes marketed medicines SPINRAZA (nusinersen) for spinal muscular atrophy (search), WAINUA (eplontersen) for hereditary transthyretin-mediated amyloid polyneuropathy (search), and QALSODY (tofersen) for SOD1-ALS (search). The company's clinical-stage portfolio includes 12 investigational medicines in neurology, with six wholly owned by Ionis.
New additional data from the pivotal study will be presented at the 2026 American Academy of Neurology annual meeting in Chicago, Illinois, providing further insights into zilganersen's therapeutic potential for this devastating rare disease.